Literature DB >> 14585212

Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: in vitro expression and immune responses in DNA-vaccinated mice.

Feng Gao1, Yingying Li, Julie M Decker, Fred W Peyerl, Frederic Bibollet-Ruche, Cynthia M Rodenburg, Yalu Chen, Denise R Shaw, Susan Allen, Rosemary Musonda, George M Shaw, Allan J Zajac, Norman Letvin, Beatrice H Hahn.   

Abstract

Codon usage optimization of human immunodeficiency virus type 1 (HIV-1) structural genes has been shown to increase protein expression in vitro as well as in the context of DNA vaccines in vivo; however, all optimized genes reported thus far are derived from HIV-1 (group M) subtype B viruses. Here, we report the generation and biological characterization of codon usage-optimized gag, pol, env (gp160, gp140, gp120), and nef genes from a primary (nonrecombinant) HIV-1 subtype C isolate. After transfection into 293T cells, optimized subtype C genes expressed one to two orders of magnitude more protein (as determined by immunoblot densitometry) than the corresponding wild-type constructs. This effect was most pronounced for gp160, gp140, Gag, and Pol (>250-fold), but was also observed for gp120 and Nef (45- and 20-fold, respectively). Optimized gp160- and gp140-derived glycoproteins were processed, incorporated into virus particles, and mediated virus entry when expressed in trans to complement an env-minus HIV-1 provirus. Mice immunized with optimized gp140 DNA developed antibody as well as CD4+ and CD8+ T cell immune responses that were orders of magnitude greater than those of mice immunized with wild-type gp140 DNA. These data confirm and extend previous studies of codon usage optimization of HIV-1 genes to the most prevalent group M subtype. Our panel of matched optimized and wild-type subtype C genes should prove valuable for studies of protein expression and function, the generation of subtype-specific immunological reagents, and the production of DNA-based sub-unit vaccines directed against a broader spectrum of viruses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585212     DOI: 10.1089/088922203769232610

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  63 in total

Review 1.  Codon-optimized reading frames facilitate high-level expression of the HIV-1 minor proteins.

Authors:  D S Anson; K R Dunning
Journal:  Mol Biotechnol       Date:  2005-09       Impact factor: 2.695

2.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

3.  Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.

Authors:  Denise L Kothe; Julie M Decker; Yingying Li; Zhiping Weng; Frederic Bibollet-Ruche; Kenneth P Zammit; Maria G Salazar; Yalu Chen; Jesus F Salazar-Gonzalez; Zina Moldoveanu; Jiri Mestecky; Feng Gao; Barton F Haynes; George M Shaw; Mark Muldoon; Bette T M Korber; Beatrice H Hahn
Journal:  Virology       Date:  2006-11-13       Impact factor: 3.616

4.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.

Authors:  Jiri Mestecky; Peter F Wright; Lucia Lopalco; Herman F Staats; Pamela A Kozlowski; Zina Moldoveanu; Rashada C Alexander; Rose Kulhavy; Claudia Pastori; Leonard Maboko; Gabriele Riedner; Yuwei Zhu; Terri Wrinn; Michael Hoelscher
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-22       Impact factor: 2.205

6.  Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responses.

Authors:  Milan Raska; Zina Moldoveanu; Jan Novak; Zdenek Hel; Lea Novak; Jadranka Bozja; Richard W Compans; Chinglai Yang; Jiri Mestecky
Journal:  Vaccine       Date:  2008-02-07       Impact factor: 3.641

7.  Proteolytic activation of the 1918 influenza virus hemagglutinin.

Authors:  Chawaree Chaipan; Darwyn Kobasa; Stephanie Bertram; Ilona Glowacka; Imke Steffen; Theodros Solomon Tsegaye; Makoto Takeda; Thomas H Bugge; Semi Kim; Youngwoo Park; Andrea Marzi; Stefan Pöhlmann
Journal:  J Virol       Date:  2009-01-21       Impact factor: 5.103

8.  Identification of two HIV inhibitors that also inhibit human RNaseH2.

Authors:  Junghwan Kim; Jaewan Yoon; MoonKyeong Ju; Yunmi Lee; Tae-Hee Kim; Junwon Kim; Peter Sommer; Zaesung No; Jonathan Cechetto; Sung-Jun Han
Journal:  Mol Cells       Date:  2013-09-02       Impact factor: 5.034

9.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

10.  Severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as a receptor for pH-dependent entry into human and animal cell lines.

Authors:  Heike Hofmann; Xingxing Li; Xiaoai Zhang; Wei Liu; Annika Kühl; Franziska Kaup; Samantha S Soldan; Francisco González-Scarano; Friedemann Weber; Yuxian He; Stefan Pöhlmann
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.